Arbutus Biopharma Corp 8-K

What Happened

• On February 2, 2026, the U.S. District Court for the District of Delaware issued a memorandum and order in litigation brought by Arbutus Biopharma Corporation and its licensee Genevant Sciences GmbH against Moderna Inc. and a Moderna affiliate. The suit seeks damages for alleged infringement of several U.S. patents in the manufacture and sale of Moderna’s COVID-19 vaccine, mRNA-1273.
• The court’s memorandum and order addressed multiple motions for summary judgment and requests to exclude expert testimony. A copy of the memorandum and order is filed with the 8-K as Exhibit 99.1 and is incorporated by reference.

Key Details

• Date of court memorandum and order: February 2, 2026.
• Parties: Arbutus Biopharma Corporation and licensee Genevant vs. Moderna Inc. and a Moderna affiliate.
• Patents asserted: U.S. Patent Nos. 8,058,069; 8,492,359; 8,822,668; 9,364,435; 9,504,651; and 11,141,378.
• Filing: Item 8.01 (Other Events) discloses the court order; Exhibit 99.1 contains the full memorandum and order.

Why It Matters

• This filing notifies investors that a federal court has issued substantive rulings in a material patent lawsuit where Arbutus and its licensee seek damages related to Moderna’s mRNA-1273 vaccine. Court decisions on summary judgment and expert testimony can materially affect the strength of the parties’ cases and potential remedies.
• The 8-K does not disclose monetary damages or an immediate financial impact; the memorandum and order (Exhibit 99.1) should be reviewed for specific rulings and next steps in the litigation.